Last reviewed · How we verify
Dexamethasone low dose
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus), Adrenocortical insufficiency, Cerebral edema.
At a glance
| Generic name | Dexamethasone low dose |
|---|---|
| Sponsor | Manuel Taboada Muñiz |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology, Oncology (supportive care) |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone enters cells and binds to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory responses. Low-dose formulations are used to minimize systemic side effects while maintaining therapeutic benefit.
Approved indications
- Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus)
- Adrenocortical insufficiency
- Cerebral edema
- Allergic reactions and anaphylaxis
- Supportive care in cancer chemotherapy (nausea/vomiting prevention)
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (anxiety, irritability)
- Increased infection risk
- Osteoporosis (with chronic use)
- Gastrointestinal upset
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss (PHASE1, PHASE2)
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (PHASE2)
- Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer (PHASE2, PHASE3)
- LBL-2016 for Children or Adolescents in China (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone low dose CI brief — competitive landscape report
- Dexamethasone low dose updates RSS · CI watch RSS
- Manuel Taboada Muñiz portfolio CI